The utility of in vitro data in making accurate predictions of human p-glycoprotein-mediated drug-drug interactions: A case study for AZD5672

Drug Metabolism and Disposition

Volumn 39, Issue 2, 2011, Pages 275-282

  Elsby, Robert ^a   Gillen, Michael ^a   Butters, Caroline ^a   Imisson, Gemma ^a   Sharma, Pradeep ^a   Smith, Veronica ^a   Surry, Dominic D ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 5672; DIGOXIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; KETOCONAZOLE; QUINIDINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG TRANSPORT; HUMAN; IN VITRO STUDY; PREDICTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BENZENEACETAMIDES; BIOLOGICAL TRANSPORT; CACO-2 CELLS; DIGOXIN; DRUG DESIGN; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; P-GLYCOPROTEIN; SUBSTRATE SPECIFICITY; SULFONAMIDES; YOUNG ADULT;

EID: 79251518645     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035881     Document Type: Article

References (26)

1. Alderman CP and Allcroft PD (1997) Digoxin-itraconazole interaction: possible mechanisms. Ann Pharmacother 31:438-440.
2. Balimane PV, Marino A, and Chong S (2008) P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate? AAPS J 10:577-586.
3. Cavet ME, West M, and Simmons NL (1996) Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 118:1389-1396.
4. 50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm 7:398-411.
5. Elsby R, Surry DD, Smith VN, and Gray AJ (2008) Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 38:1140-1164.
6. Eyal S, Hsiao P, and Unadkat JD (2009) Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther 123:80-104.
7. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, and Lee CA (2009) Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 85:173-181.
8. Fromm MF, Kim RB, Stein CM, Wilkinson GR, and Roden DM (1999) Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99:552-557.
9. Gerlag DM, Hollis S, Layton M, Vencovsky J, Szekanecz Z, Braddock M, and Tak PP (2010) Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. Arthritis Rheum 62:3154-3160.
10. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, et al. (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
11. Hedman A, Angelin B, Arvidsson A, Dahlqvist R, and Nilsson B (1990) Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin Pharmacol Ther 47:20-26.
12. Hollander M and Wolfe DA (1999) Nonparametric Statistical Methods, 2nd ed, John Wiley & Sons, New York.
13. Igel S, Drescher S, Mürdter T, Hofmann U, Heinkele G, Tegude H, Glaeser H, Brenner SS, Somogyi AA, Omari T, et al. (2007) Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux. Clin Pharmacokinet 46:777-785.
14. Jalava KM, Partanen J, and Neuvonen PJ (1997) Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 19:609-613.
15. Kovarik JM, Rigaudy L, Guerret M, Gerbeau C, and Rost KL (1999) Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin Pharmacol Ther 66:391-400.
16. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, and Hagenbuch B (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525-533.
17. Lacarelle B, Rahmani R, de Sousa G, Durand A, Placidi M, and Cano JP (1991) Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes. Fundam Clin Pharmacol 5:567-582.
18. Mizuno N, Niwa T, Yotsumoto Y, and Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425-461.
19. Sadeque AJ, Wandel C, He H, Shah S, and Wood AJ (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231-237.
20. Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36:179-194.
21. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
22. Tuncok Y, Hazan E, Oto O, Guven H, Catalyurek H, and Kalkan S (1997) Relationship between high serum digoxin levels and toxicity. Int J Clin Pharmacol Ther 35:366-368.
23. van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, and Brouwers JR (2009) An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists. Clin Ther 31:1737-1746.
24. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, and Siegmund W (2000) Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68:6-12.
25. Zhang L, Strong JM, Qiu W, Lesko LJ, and Huang SM (2006) Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm 3:62-69.
26. Zhang L, Zhang YD, Strong JM, Reynolds KS, and Huang SM (2008) A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709-724.